The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world comparison of the efficacy of three CDK4/6 inhibitors (CDK4/6i) in the first-line treatment of endocrine-sensitive advanced breast cancer (aBC): Single institution experience.
 
Natalija Dedic Plavetic
Honoraria - AstraZeneca; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Swixx BioPharma
Consulting or Advisory Role - AstraZeneca; MSD; Novartis; Swixx BioPharma
Speakers' Bureau - AstraZeneca; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - MSD; Novartis; Pfizer; Roche
 
Katarina Čular
Research Funding - Roche
Travel, Accommodations, Expenses - Novartis
 
Dora Gudelj
Research Funding - MSD; Roche
 
Kristina Kaceljak
Travel, Accommodations, Expenses - Novartis
 
Marija Križić
Honoraria - Roche; SERVIER
Speakers' Bureau - Gilead Sciences
Research Funding - Novartis (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Medicopharmacia
 
Marina Popovic
Honoraria - AstraZeneca; Gilead Sciences; Novartis; Pfizer (I); Roche
Speakers' Bureau - Gilead Sciences
Research Funding - Novartis; Roche
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences
 
Stela Bulimbašić
Travel, Accommodations, Expenses - MSD
 
Maja Sirotković-Skerlev
No Relationships to Disclose
 
Sanda Bubanović
No Relationships to Disclose
 
Tajana Silovski
Consulting or Advisory Role - Pfizer; Swixx BioPharma
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Roche
Research Funding - Pierre Fabre; Roche
Travel, Accommodations, Expenses - AstraZeneca; Roche